Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of topical HDIT101 versus placebo for recurrent orolabial HSV-1
2020-000926-24Phase 2Terminated
- Sponsor
- Heidelberg ImmunoTherapeutics
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Herpes simplex virus type 1 infection and herpes labialis comparing HDIT101 topical with Placebo topical (2 arms). Primary endpoint: Clinical efficacy objective. Started Jun 2020; status: terminated.
02
Drugs
HDIT101
03
Conditions
Herpes simplex virus type 1 infectionherpes labialis
Beyond the preview
Go deeper on 2020-000926-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000926-24.